Product name: Curculigoside
Synonym name:
Catalogue No.: BP0419
Cas No.: 85643-19-2
Formula: C₂₂H₂₆O₁₁
Mol Weight: 466.439
Botanical Source: Curculigo orchioides Gaertn.
Physical Description:
Type of Compound: Phenols

Purity: 95%~99%
Analysis Method: HPLC-DAD or/and HPLC-ELSD
Identification Method: Mass, NMR
Packing: Brown vial or HDPE plastic bottle

Storage: Store in a well closed container, protected from air and light. Put into refrigerate or freeze for long term storage.
Whenever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20℃. Generally, these will be useable for up to two weeks.

The product could be supplied from milligrams to grams
Inquire for bulk scale.

Description:

Curculigoside has potent antioxidant, anti-osteoporotic, immunomodulatory, and neuroprotective effects. Curculigoside can improve cognitive function in aged animals, possibly by decreasing the activity of AchE in the cerebra and inhibiting the expression of BACE1 in the hippocampus. Curculigoside exhibits potent inhibitory activity against matrix metalloproteinase-1 in cultured human skin fibroblasts, and increases the levels of ALP and Runx2 in osteoblasts under oxidative stress via anti-oxidative character.

References:

Stem Cells Dev. 2014 Jan 15;23(2):146-54.    

Curculigoside improves osteogenesis of human amniotic fluid-derived stem cells.   

Curculigoside, a phenolic glycoside, is the main active compound of Curculigo orchioides (Amaryllidaceae, rhizome). C. orchioides is a traditional Chinese herbal medicine and has been commonly used to treat orthopedic disorders and bone healing in Asia. This study evaluated the effect of Curculigoside on osteogenic differentiation of human amniotic fluid-derived stem cells (hAFSCs). 

METHODS AND RESULTS:

The results showed that Curculigoside stimulated alkaline phosphatase activity and calcium deposition of hAFSCs during osteogenic differentiation in a dose-dependent manner (1-100 μg/mL), while the effects were reduced at the higher concentration of 200 μg/mL. From reverse transcriptase-polymerase chain reaction analysis, the osteogenic genes osteopontin (OPN) and Collagen I were upregulated with Curculigoside treatment (1-100 μg/mL). Concurrently, the ratio of osteoprotegerin (OPG) to receptor activator of nuclear factor kappa-B ligand (RANKL) was increased, indicating the inhibition of osteoclastogenesis by Curculigoside. Moreover, the role of Wnt/β-catenin signaling during Curculigoside treatment was revealed by the upregulation of β-catenin and Cyclin D1. 

CONCLUSIONS:

In summary, Curculigoside improved osteogenesis and inhibited osteoclastogenesis of hAFSCs, suggesting its potential use to regulate hAFSC osteogenic differentiation for treating bone disorders.    

J Ethnopharmacol. 2010 Oct 28;132(1):233-9.    

Curculigoside attenuates human umbilical vein endothelial cell injury induced by H2O2.   

Vessel endothelium injury caused by reactive oxygen species (ROS) including H(2)O(2) plays a critical role in the pathogenesis of cardiovascular disorders. Therefore, agents or antioxidants that can inhibit production of ROS has highly clinical values in cardiovascular therapy. Curculigoside is the major bioactive compounds present in Curculigo orchioides, and possess potent antioxidant properties against oxidative stress insults through undefined mechanism(s). The present study was designed to test the hypothesis that Curculigoside can inhibit H(2)O(2)-induced injury in human umbilical vein endothelial cells. 

METHODS AND RESULTS:

Human umbilical vein endothelial cells (HUVECs) were treated with Curculigoside in the presence/absence of hydrogen peroxide (H(2)O(2)). The protective effects of Curculigoside OP-D against H(2)O(2) were evaluated. HUVECs incubated with 400 μM H(2)O(2) had significantly decreased the viability of endothelial cells, which was accompanied with apparent cells apoptosis, the activation of caspase-3 and the upregulation of p53 mRNA expression. In addition, H(2)O(2) treatment induced a marked increase of MDA, LDH content and in intracellular ROS, decreased the content of nitric oxide (NO) and GSH-Px activities in endothelial cells. However, pretreatment with 0.5.5,10 μM Curculigoside resulted in a significant recovery from H(2)O(2)-induced cell apoptosis. Also, it decreased other H(2)O(2)-induced damages in a concentration-dependent manner. Furthermore, pretreatment with Curculigoside decreased the activity of caspase-3 and p53 mRNA expression, which was known to play a key role in H(2)O(2)-induced cell apoptosis. 

CONCLUSIONS:

The present study shows that Curculigoside can protect endothelial cells against oxidative injury induced by H(2)O(2), suggesting that this compound may constitute a promising intervention against cardiovascular disorders.    

Arch Pharm Res. 2009 Oct;32(10):1433-9.    

The effect of curculigoside on the expression of matrix metalloproteinase-1 in cultured human skin fibroblasts.   

The dried rhizomes of Curculigo orchioides G. yielded two phenolic glycosides, Curculigoside (1), orcinol-beta-D-glucoside (4), and two cycloartane saponins, curculigosaponin G (2), curculigosaponin I (3). The structures were determined using spectroscopic methods. 

METHODS AND RESULTS:

Among these isolates, compound 1 exhibited potent inhibitory activity against matrix metalloproteinase-1 in cultured human skin fibroblasts. In addition, it increased the level of Bcl-2 protein expression and decreased the level of Bax protein expression. Compound 4 was isolated from this plant for the first time.    

J Pharm Pharmacol. 2013 Jul;65(7):1005-13.    

Curculigoside promotes osteogenic differentiation of bone marrow stromal cells from ovariectomized rats.   

Curculigoside, a natural compound isolated from the medicinal plant Curculigo orchioides has been reported to prevent bone loss in ovariectomized rats. However, the underlying molecular mechanisms are largely unknown. This study investigated the effects of Curculigoside on proliferation and osteogenic differentiation of bone marrow stromal cells (BMSCs). 

METHODS AND RESULTS:

The toxicity, proliferation and osteogenic differentiation of BMSCs cultured with various concentrations (0 as control, 10, 100 and 500 μm) of Curculigoside were measured by viability assay, MTT analysis, alkaline phosphatase (ALP) activity assay, alizarin red staining and mineralization assay, real-time PCR analysis on osteogenic genes including ALP, type I collagen (Col I), osteocalcin (OCN) and osteoprotegerin (OPG), runt-related transcription factor 2 (Runx2), as well as OPG enzyme-linked immunosorbent assay. No significant cytotoxicity was observed for BMSCs after supplementation with Curculigoside. The proliferation of BMSCs was enhanced after administration of Curculigoside, especially 100 μm Curculigoside. Moreover, the osteogenic gene expression was significantly enhanced with 100 μm Curculigoside treatment. Importantly, Curculigoside significantly increased OPG secretion. 

CONCLUSIONS:

The data indicate that Curculigoside could promote BMSC proliferation and induce osteogenic differentiation of BMSCs. The most profound response was observed with 100 μm Curculigoside. These findings may be valuable for understanding the mechanism of the effect of Curculigoside on bone, especially in relation to osteoporosis.